Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $14.00 price target on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Tuesday.

Coya Therapeutics Trading Up 0.3 %

NASDAQ COYA opened at $6.47 on Thursday. The company has a market cap of $108.09 million, a P/E ratio of -9.95 and a beta of 0.31. The company has a fifty day simple moving average of $6.31 and a 200 day simple moving average of $6.48. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million. Sell-side analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. DME Capital Management LP lifted its position in shares of Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after buying an additional 372,414 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics during the fourth quarter valued at approximately $74,000. Northern Trust Corp lifted its holdings in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares during the period. Tower Research Capital LLC TRC boosted its position in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Coya Therapeutics in the 4th quarter valued at $59,000. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.